Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
No open-market purchases or sales by Werewolf Therapeutics, Inc. insiders were filed in the last 90 days; 46 institutions reported holding it in 13F filings for Q3 2026, worth $11.9M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $46.0M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +1 vs. previous quarter
- 46
- 13F valueReported value at the end of Q3 2026
- $11.9M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$60.8M
- No comparable prior period
- Free cash flow, FY2025
- -$60.3M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.13M
- Shares sold short
- Change
- −227.6K
- −9.7% vs. previous
- Days to cover
- 6.39
- At average daily volume
Superinvestors holding HOWL, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding HOWL at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Werewolf Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2026 (view filing)5:34 PM ET | Jul 6-7 | 2 days | Evnin LukeDirector | SSale | −143.2K | $0.3125 | −$44.7K | −100.0%0 after | 2 lots10b5-1 |
| Jun 29, 2026 (view filing)7:07 PM ET | Jun 29 | Same day | Evnin LukeDirector | SSale | −157.1K | $0.30 | −$47.1K | −52.3%143.2K after | 10b5-1 |
| Jun 22, 2026 (view filing)6:59 PM ET | Jun 17 | 5 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −416.9K | $0.35 | −$145.9K | −57.9%303.7K after | 2 lots |
| Jun 16, 2026 (view filing)6:01 PM ET | Jun 12-16 | 4 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −448.8K | $0.3871 | −$173.8K | −57.5%331.4K after | 6 lots |
| Jun 11, 2026 (view filing)8:13 PM ET | Jun 9-11 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −678.2K | $0.3739 | −$253.6K | −65.2%361.2K after | 6 lots |
| Jun 10, 2026 (view filing)5:20 PM ET | Jun 9 | 1 day | Evnin LukeDirector | SSale | −76.9K | $0.37 | −$28.5K | −20.4%300.3K after | 10b5-1 |
| Jun 8, 2026 (view filing)6:13 PM ET | Jun 4-8 | 4 days | Evnin LukeDirector | SSale | −105.6K | $0.4076 | −$43.0K | −21.9%377.2K after | 3 lots10b5-1 |
| Jun 3, 2026 (view filing)6:42 PM ET | Jun 1-3 | 2 days | Evnin LukeDirector | SSale | −139.8K | $0.4551 | −$63.6K | −22.5%482.8K after | 3 lots10b5-1 |
| May 29, 2026 (view filing)6:51 PM ET | May 27-29 | 2 days | Evnin LukeDirector | SSale | −141.1K | $0.4692 | −$66.2K | −18.5%622.6K after | 3 lots10b5-1 |
| May 26, 2026 (view filing)6:18 PM ET | May 21-26 | 5 days | Evnin LukeDirector | SSale | −191.8K | $0.4514 | −$86.6K | −20.1%763.7K after | 3 lots10b5-1 |
Top 10 13F holders, Q3 2026
See all 46 holdersThe largest institutional positions in Werewolf Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Balyasny Asset Management LLC | 3,040,251 | $2.80M | 0.01% | +1,250,162+69.8% | Added |
| ADAR1 Capital Management, LLC | 2,023,331 | $1.87M | 0.08% | +2,023,331 | New |
| Vanguard Capital Management LLC | 1,217,976 | $1.12M | 0.00% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 657,786 | $606.7K | 0.09% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 626,810 | $578.1K | 0.09% | 00.0% | Unchanged |
| DC Funds, LP | 589,102 | $543.3K | 73.28% | 00.0% | Unchanged |
| Jane Street Group, LLC | 564,526 | $520.7K | 0.00% | +312,689+124.2% | Added |
| Citadel Advisors LLC | 553,702 | $510.7K | 0.00% | +553,702 | New |
| Renaissance Technologies LLC | 550,935 | $508.1K | 0.00% | −123,697−18.3% | Reduced |
| HRT Financial LP | 415,191 | $382.0K | 0.00% | +415,191 | New |
Holders of 5% or more of HOWL
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Werewolf Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Balyasny Asset Management LLC | 13G | 6.26%3.04M shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |
| Moll Peter | 13G | 5.20%2.54M shares | New | Sep 21, 20261 filing | Sep 21, 2026 | SEC |